Replies to post #204957 on Biotech Values

[mcbio]

SMMT -

I don't follow them that closely so I could be wrong. I had the impression the most likely event was a capital raise, followed by partnering their antibiotic with this not even being on the horizon.

All of those were certainly possibilities. But the multiple articles talking about SRPT's interest in a broad-acting DMD drug and fact that utrophin was specifically cited was part of why I thought this partnership had a good chance of coming to fruition.

As far as telegraphing deals I know you owned a company (I briefly had a small position) where the CEO was very specific about doing a deal and then meeting that timeline! In fact I think he did that on a couple of occasions....ARRY sound familiar?

Yes, you have a good memory. ARRY did this on a few occasions. I think the deal with AMGN on the glucokinase activator for diabetes caused a 30 or 40% pop in shares. This is why, for me, it's always important to pay close attention to CCs for clues from management, if not outright guidance, on events to come. You can also look for shifts in management tone, in general or on specific drugs for clues as to how things may be going.

Anyway congratulations on SMMT! Guess its still a high reward, high risk play.

Thanks and yes, absolutely.